Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | GRO-a | 7833.0 | 64 | |
N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | GRO-a | 2492.5 | 44 | |
N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | GRO-a | 4221.0 | 70 | |
RA2159 | IGF-I | 100 | ug/mL | 3 | GRO-a | 4280.0 | 61 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 2731.5 | 52 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 3219.0 | 67 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 5052.0 | 53 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 5779.0 | 61 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 3035.0 | 57 | |
RA2159 | 3 | GRO-a | 5747.5 | 74 | |||||||
N2586 | IGF-I | 100 | ug/mL | 3 | GRO-a | 10304.0 | 59 | ||||
N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 8217.5 | 62 | |
N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 7403.5 | 68 | |
N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 8766.0 | 71 | |
N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 2270.5 | 62 | |
N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | GRO-a | 4455.0 | 62 | |
N2586 | 3 | GRO-a | 10104.0 | 55 | |||||||
RA2159 | EGF | 100 | ng/mL | 3 | GRO-a | 6112.0 | 69 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | GRO-a | 3950.0 | 60 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | GRO-a | 6384.5 | 80 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | GRO-a | 6539.0 | 54 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | GRO-a | 7553.5 | 68 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | GRO-a | 2965.0 | 64 | |
RA2159 | JNK-IN-11 | 0.3 | uM | 3 | GRO-a | 4072.5 | 62 | ||||
N2586 | EGF | 100 | ng/mL | 3 | GRO-a | 11421.5 | 68 |